ACTM-838
Advanced Solid Tumors
Phase 1a/1bActive
Key Facts
About Actym Therapeutics
Actym Therapeutics is a private, clinical-stage biotech developing the STACT™ platform, a systemically administered, engineered bacterial delivery system designed to localize in tumors and produce immunotherapies on-site to avoid systemic toxicity. The company's lead candidate, ACTM-838, is in Phase 1 trials for solid tumors, targeting a major unmet need in immuno-oncology. Backed by notable venture capital investors and led by a team with deep expertise, Actym aims to overcome tumor resistance by harnessing the innate intelligence of bacteria to create potent and localized immune responses.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |